DK3183337T3 - Use of Jagged 1 / Frizzled 4 as cell surface marker for isolation of human cardiac ventricular progenitor cells - Google Patents
Use of Jagged 1 / Frizzled 4 as cell surface marker for isolation of human cardiac ventricular progenitor cells Download PDFInfo
- Publication number
- DK3183337T3 DK3183337T3 DK15759585.1T DK15759585T DK3183337T3 DK 3183337 T3 DK3183337 T3 DK 3183337T3 DK 15759585 T DK15759585 T DK 15759585T DK 3183337 T3 DK3183337 T3 DK 3183337T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- human
- cardiac
- jagged
- cell
- Prior art date
Links
- 230000002861 ventricular Effects 0.000 title claims description 281
- 241000282414 Homo sapiens Species 0.000 title claims description 269
- 210000000130 stem cell Anatomy 0.000 title claims description 258
- 230000000747 cardiac effect Effects 0.000 title claims description 217
- 102000001003 Frizzled-4 Human genes 0.000 title claims description 166
- 108050007986 Frizzled-4 Proteins 0.000 title claims description 166
- 108700003486 Jagged-1 Proteins 0.000 title claims description 162
- 108700037966 Protein jagged-1 Proteins 0.000 title claims description 159
- 239000002458 cell surface marker Substances 0.000 title description 10
- 238000002955 isolation Methods 0.000 title description 8
- 102000049556 Jagged-1 Human genes 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims description 522
- 102100032702 Protein jagged-1 Human genes 0.000 claims description 170
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 claims description 106
- 238000000034 method Methods 0.000 claims description 103
- 230000004069 differentiation Effects 0.000 claims description 87
- 239000003795 chemical substances by application Substances 0.000 claims description 83
- 230000014509 gene expression Effects 0.000 claims description 69
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 65
- 210000002216 heart Anatomy 0.000 claims description 59
- 238000001727 in vivo Methods 0.000 claims description 57
- 238000012360 testing method Methods 0.000 claims description 57
- 238000000338 in vitro Methods 0.000 claims description 31
- 210000000056 organ Anatomy 0.000 claims description 26
- 238000012258 culturing Methods 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 21
- 230000004217 heart function Effects 0.000 claims description 20
- 210000005260 human cell Anatomy 0.000 claims description 20
- 210000003734 kidney Anatomy 0.000 claims description 20
- 239000011159 matrix material Substances 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 claims description 15
- KHZOJCQBHJUJFY-UHFFFAOYSA-N 2-[4-(2-methylpyridin-4-yl)phenyl]-n-(4-pyridin-3-ylphenyl)acetamide Chemical compound C1=NC(C)=CC(C=2C=CC(CC(=O)NC=3C=CC(=CC=3)C=3C=NC=CC=3)=CC=2)=C1 KHZOJCQBHJUJFY-UHFFFAOYSA-N 0.000 claims description 14
- 206010048610 Cardiotoxicity Diseases 0.000 claims description 14
- 231100000259 cardiotoxicity Toxicity 0.000 claims description 14
- 230000007681 cardiovascular toxicity Effects 0.000 claims description 14
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 210000003716 mesoderm Anatomy 0.000 claims description 13
- 238000004113 cell culture Methods 0.000 claims description 11
- 208000019622 heart disease Diseases 0.000 claims description 11
- 208000020446 Cardiac disease Diseases 0.000 claims description 10
- 230000001988 toxicity Effects 0.000 claims description 10
- 231100000419 toxicity Toxicity 0.000 claims description 10
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 claims description 9
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 claims description 9
- 208000010125 myocardial infarction Diseases 0.000 claims description 9
- 101150114527 Nkx2-5 gene Proteins 0.000 claims description 8
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 claims description 8
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 claims description 7
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 108010068426 Contractile Proteins Proteins 0.000 claims description 6
- 101100540419 Danio rerio kdrl gene Proteins 0.000 claims description 4
- 101710107751 Myelin expression factor 2 Proteins 0.000 claims description 4
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000002771 cell marker Substances 0.000 claims description 2
- 210000001557 animal structure Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 61
- 210000004413 cardiac myocyte Anatomy 0.000 description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 43
- 239000003550 marker Substances 0.000 description 42
- 239000002609 medium Substances 0.000 description 37
- 101150070110 Isl1 gene Proteins 0.000 description 36
- 238000011282 treatment Methods 0.000 description 36
- 208000024172 Cardiovascular disease Diseases 0.000 description 35
- 230000001625 cardiomyogenic effect Effects 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 30
- 201000010099 disease Diseases 0.000 description 29
- 238000002054 transplantation Methods 0.000 description 29
- 210000003205 muscle Anatomy 0.000 description 28
- 239000003112 inhibitor Substances 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 23
- 230000006870 function Effects 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 210000000663 muscle cell Anatomy 0.000 description 20
- 210000004165 myocardium Anatomy 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 102000013814 Wnt Human genes 0.000 description 17
- 108050003627 Wnt Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- 101150113031 Jag1 gene Proteins 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 230000037361 pathway Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 239000005090 green fluorescent protein Substances 0.000 description 14
- 101150090422 gsk-3 gene Proteins 0.000 description 14
- 101000994439 Danio rerio Protein jagged-1a Proteins 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 210000001671 embryonic stem cell Anatomy 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 11
- 241001529936 Murinae Species 0.000 description 10
- 238000003559 RNA-seq method Methods 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 230000002526 effect on cardiovascular system Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 238000012744 immunostaining Methods 0.000 description 9
- 108060000903 Beta-catenin Proteins 0.000 description 8
- 102000015735 Beta-catenin Human genes 0.000 description 8
- 102100026057 Myosin regulatory light chain 2, atrial isoform Human genes 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000001746 atrial effect Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 210000005003 heart tissue Anatomy 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000001704 mesoblast Anatomy 0.000 description 8
- 210000002894 multi-fate stem cell Anatomy 0.000 description 8
- 108010085895 Laminin Proteins 0.000 description 7
- 102000007547 Laminin Human genes 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 101710098224 Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000000453 cell autonomous effect Effects 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- -1 CDID Proteins 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 6
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002458 fetal heart Anatomy 0.000 description 6
- 210000002064 heart cell Anatomy 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 101000629402 Homo sapiens Mesoderm posterior protein 1 Proteins 0.000 description 5
- 102100026822 Mesoderm posterior protein 1 Human genes 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000008790 VE-cadherin Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000004504 adult stem cell Anatomy 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 108010018828 cadherin 5 Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000005239 tubule Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 4
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 4
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 4
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 108010076089 accutase Proteins 0.000 description 4
- 206010000891 acute myocardial infarction Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000012137 double-staining Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 208000015210 hypertensive heart disease Diseases 0.000 description 4
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 208000037891 myocardial injury Diseases 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 210000005167 vascular cell Anatomy 0.000 description 4
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 3
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 3
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 description 3
- 206010011703 Cyanosis Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 3
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 3
- 101000977765 Homo sapiens Iroquois-class homeodomain protein IRX-4 Proteins 0.000 description 3
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 3
- 101000958741 Homo sapiens Myosin-6 Proteins 0.000 description 3
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 3
- 101000764260 Homo sapiens Troponin T, cardiac muscle Proteins 0.000 description 3
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102100023531 Iroquois-class homeodomain protein IRX-4 Human genes 0.000 description 3
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 3
- 102100038319 Myosin-6 Human genes 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 3
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000012574 advanced DMEM Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000005829 chemical entities Chemical class 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 208000028831 congenital heart disease Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 206010042772 syncope Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 2
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 108010049990 CD13 Antigens Proteins 0.000 description 2
- 102100024209 CD177 antigen Human genes 0.000 description 2
- 102100036008 CD48 antigen Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102100021261 Frizzled-10 Human genes 0.000 description 2
- 102100021265 Frizzled-2 Human genes 0.000 description 2
- 102100039676 Frizzled-7 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100039990 Hairy/enhancer-of-split related with YRPW motif protein 2 Human genes 0.000 description 2
- 101100339679 Hevea brasiliensis HRT2 gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- 101000819451 Homo sapiens Frizzled-10 Proteins 0.000 description 2
- 101000819477 Homo sapiens Frizzled-2 Proteins 0.000 description 2
- 101000885797 Homo sapiens Frizzled-7 Proteins 0.000 description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 description 2
- 101000739767 Homo sapiens Semaphorin-7A Proteins 0.000 description 2
- 101000799194 Homo sapiens Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 101000946833 Homo sapiens T-cell surface glycoprotein CD8 beta chain Proteins 0.000 description 2
- 101000830600 Homo sapiens Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100032817 Integrin alpha-5 Human genes 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 description 2
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 2
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108091006313 SLC3A2 Proteins 0.000 description 2
- 102100037545 Semaphorin-7A Human genes 0.000 description 2
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 102100034928 T-cell surface glycoprotein CD8 beta chain Human genes 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 102100024585 Tumor necrosis factor ligand superfamily member 13 Human genes 0.000 description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 2
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000032459 dedifferentiation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 101150061866 hey2 gene Proteins 0.000 description 2
- 230000006266 hibernation Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000009023 sarcolipin Human genes 0.000 description 2
- 108010088766 sarcolipin Proteins 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000003904 Caveolin 3 Human genes 0.000 description 1
- 108090000268 Caveolin 3 Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- 108700029231 Developmental Genes Proteins 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 206010019315 Heart transplant rejection Diseases 0.000 description 1
- 102100024208 Homeobox protein MIXL1 Human genes 0.000 description 1
- 101001052462 Homo sapiens Homeobox protein MIXL1 Proteins 0.000 description 1
- 101001120813 Homo sapiens Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 1
- 101000629029 Homo sapiens Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 description 1
- 101001030243 Homo sapiens Myosin-7 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000801260 Homo sapiens Troponin C, slow skeletal and cardiac muscles Proteins 0.000 description 1
- 101000851334 Homo sapiens Troponin I, cardiac muscle Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000011948 Multi-organ disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 1
- 102100038934 Myosin-7 Human genes 0.000 description 1
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 1
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 102000013534 Troponin C Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010047118 Wnt Receptors Proteins 0.000 description 1
- 102000006757 Wnt Receptors Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 208000019269 advanced heart failure Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 101150105254 nkx-2.5 gene Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 102000005681 phospholamban Human genes 0.000 description 1
- 108010059929 phospholamban Proteins 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000009719 regenerative response Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040892P | 2014-08-22 | 2014-08-22 | |
| US201562194016P | 2015-07-17 | 2015-07-17 | |
| PCT/US2015/046309 WO2016029122A1 (en) | 2014-08-22 | 2015-08-21 | Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3183337T3 true DK3183337T3 (en) | 2019-04-01 |
Family
ID=54062813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15759585.1T DK3183337T3 (en) | 2014-08-22 | 2015-08-21 | Use of Jagged 1 / Frizzled 4 as cell surface marker for isolation of human cardiac ventricular progenitor cells |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10597637B2 (enExample) |
| EP (2) | EP3524673A1 (enExample) |
| JP (2) | JP6738808B2 (enExample) |
| DK (1) | DK3183337T3 (enExample) |
| MA (1) | MA40589A (enExample) |
| WO (1) | WO2016029122A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016029122A1 (en) | 2014-08-22 | 2016-02-25 | Chien Kenneth R | Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
| US10596200B2 (en) | 2014-08-22 | 2020-03-24 | Procella Therapeutics Ab | Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
| DK3417073T3 (da) * | 2016-02-19 | 2023-10-30 | Procella Therapeutics Ab | Genetiske markører til transplantation af humane, hjerteventrikulære progenitorceller |
| WO2017192606A1 (en) * | 2016-05-02 | 2017-11-09 | Emory University | Methods of producing specialized cardio-like cells from stem cell |
| EP3519559A1 (en) * | 2016-09-30 | 2019-08-07 | Wisconsin Alumini Research Foundation | Primed cardiac progenitors and methods for making and using same |
| US10508263B2 (en) * | 2016-11-29 | 2019-12-17 | Procella Therapeutics Ab | Methods for isolating human cardiac ventricular progenitor cells |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| JP7275109B2 (ja) * | 2017-08-23 | 2023-05-17 | プロセラ セラピューティクス アーベー | ニューロピリン－１（ｎｒｐ１）のヒト心室前駆細胞を単離するための細胞表面マーカーとしての使用 |
| CN109189051A (zh) * | 2018-10-29 | 2019-01-11 | 江苏罗思韦尔电气有限公司 | 一种基于T-Box的故障存储及处理方法 |
| WO2023278382A1 (en) | 2021-06-29 | 2023-01-05 | Staffan Holmin | Endoluminal delivery cannula |
| EP4402249A1 (en) * | 2021-09-13 | 2024-07-24 | Fujifilm Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
| US20230330264A1 (en) | 2022-04-15 | 2023-10-19 | Smartcella Solutions Ab | COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS |
| GB202314218D0 (en) | 2023-09-18 | 2023-11-01 | Astrazeneca Ab | Cell therapy |
| CN118897089B (zh) * | 2024-08-09 | 2026-02-17 | 山西医科大学 | Sarcolipin在早期无创诊断I型射血分数保留性心衰中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5561384A (en) | 1995-11-08 | 1996-10-01 | Advanced Micro Devices, Inc. | Input/output driver circuit for isolating with minimal power consumption a peripheral component from a core section |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| US7166280B2 (en) | 2000-04-06 | 2007-01-23 | Franco Wayne P | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease |
| WO2003024462A1 (en) | 2001-09-19 | 2003-03-27 | Henry Ford Health System | Cardiac transplantation of stem cells for the treatment of heart failure |
| US7745113B2 (en) | 2003-01-31 | 2010-06-29 | The Regents Of The University Of California | Use of islet 1 as a marker for isolating or generating stem cells |
| US20080038229A1 (en) | 2006-08-08 | 2008-02-14 | Minguell Jose J | Intracoronary injection of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium |
| US20100166714A1 (en) | 2006-11-02 | 2010-07-01 | The General Hospital Corporation | Cardiovascular stem cells, methods for stem cell isolation, and uses thereof |
| EP2518140A1 (en) | 2006-11-09 | 2012-10-31 | The Johns Hopkins University | Dedifferentation of adult mammalian cardiomyocytes into cardiac stem cells |
| US20080182328A1 (en) | 2006-12-19 | 2008-07-31 | The Burnham Institute | Mammalian extraembryonic endoderm cells and methods of isolation |
| EP2222837A2 (en) | 2007-02-09 | 2010-09-01 | The General Hospital Corporation | Methods for the induction of a cell to enter the islet 1+ lineage and a method for the expansion thereof |
| GB2465502B (en) | 2007-07-31 | 2013-06-26 | Es Cell Int Pte Ltd | Method for identifying and selecting cardiomyocytes |
| AU2008333972A1 (en) * | 2007-11-30 | 2009-06-11 | New York Medical College | Compositions comprising HDAC inhibitors and methods of their use in restoring stem cell function and preventing heart failure |
| US20120027807A1 (en) | 2008-10-09 | 2012-02-02 | The General Hospital Corporation | Tissue engineered myocardium and methods of production and uses thereof |
| WO2011091944A1 (en) * | 2010-01-26 | 2011-08-04 | Université Libre de Bruxelles | Tools for isolating and following cardiovascular progenitor cells |
| US20130209415A1 (en) * | 2010-06-03 | 2013-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Purified compositions of cardiovascular progenitor cells |
| US20120009158A1 (en) | 2010-06-18 | 2012-01-12 | The General Hospital Corporation | VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF |
| WO2012070014A2 (en) | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
| WO2012162741A1 (en) * | 2011-06-01 | 2012-12-06 | Monash University | Enrichment of cardiomyocytes |
| US8951798B2 (en) | 2011-10-13 | 2015-02-10 | Wisconsin Alumni Research Foundation | Generation of cardiomyocytes from human pluripotent stem cells |
| EP2826855B1 (en) | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardial sheet |
| WO2014078414A1 (en) | 2012-11-13 | 2014-05-22 | Joseph Wu | Chemically defined production of cardiomyocytes from pluripotent stem cells |
| US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| WO2015058117A1 (en) | 2013-10-18 | 2015-04-23 | Icahn School Of Medicine At Mount Sinai | Directed cardiomyocyte differentiation and ventricular specification of stem cells |
| ES2689804T3 (es) | 2013-11-20 | 2018-11-15 | Miltenyi Biotec Gmbh | Composiciones de subpoblaciones de cardiomiocitos |
| SI3105253T1 (sl) * | 2014-02-12 | 2018-10-30 | F. Hoffmann-La Roche Ag | Protitelesa anti-Jagged1 in načini njihove uporabe |
| US10208287B2 (en) * | 2014-05-01 | 2019-02-19 | Iheart Japan Corporation | CD82-positive cardiac progenitor cells |
| WO2016029122A1 (en) | 2014-08-22 | 2016-02-25 | Chien Kenneth R | Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
| US10596200B2 (en) | 2014-08-22 | 2020-03-24 | Procella Therapeutics Ab | Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
| JP2018510649A (ja) | 2015-02-17 | 2018-04-19 | ユニバーシティー ヘルス ネットワーク | 洞房結節様ペースメーカー心筋細胞および心室様心筋細胞を作製および使用するための方法 |
| DK3417073T3 (da) | 2016-02-19 | 2023-10-30 | Procella Therapeutics Ab | Genetiske markører til transplantation af humane, hjerteventrikulære progenitorceller |
| US10508263B2 (en) | 2016-11-29 | 2019-12-17 | Procella Therapeutics Ab | Methods for isolating human cardiac ventricular progenitor cells |
-
2015
- 2015-08-21 WO PCT/US2015/046309 patent/WO2016029122A1/en not_active Ceased
- 2015-08-21 DK DK15759585.1T patent/DK3183337T3/en active
- 2015-08-21 EP EP18211720.0A patent/EP3524673A1/en not_active Ceased
- 2015-08-21 MA MA040589A patent/MA40589A/fr unknown
- 2015-08-21 JP JP2017529972A patent/JP6738808B2/ja active Active
- 2015-08-21 US US14/832,324 patent/US10597637B2/en active Active
- 2015-08-21 EP EP15759585.1A patent/EP3183337B1/en active Active
-
2020
- 2020-04-22 JP JP2020076020A patent/JP2020120677A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3183337A1 (en) | 2017-06-28 |
| US10597637B2 (en) | 2020-03-24 |
| EP3524673A1 (en) | 2019-08-14 |
| JP2020120677A (ja) | 2020-08-13 |
| MA40589A (fr) | 2017-06-28 |
| JP2017525393A (ja) | 2017-09-07 |
| US20160053229A1 (en) | 2016-02-25 |
| WO2016029122A1 (en) | 2016-02-25 |
| EP3183337B1 (en) | 2019-02-06 |
| JP6738808B2 (ja) | 2020-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10597637B2 (en) | Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells | |
| JP7386290B2 (ja) | ヒト心室前駆細胞の生着のための遺伝子マーカー | |
| US11401508B2 (en) | Methods for isolating human cardiac ventricular progenitor cells | |
| US20200268803A1 (en) | Use of lifr or fgfr3 as a cell surface marker for isolating human cardiac ventricular progenitor cells | |
| JP7275109B2 (ja) | ニューロピリン－１（ｎｒｐ１）のヒト心室前駆細胞を単離するための細胞表面マーカーとしての使用 | |
| JP4377690B2 (ja) | 拍動する心筋細胞へ形質転換する幹細胞 | |
| EP3327118B1 (en) | Method for inducing vascular endothelial cells | |
| US10226487B2 (en) | Derivation and self-renewal of lsl1+ cells and uses thereof | |
| WO2011153236A1 (en) | Purified compositions of cardiovascular progenitor cells | |
| JP6989591B2 (ja) | 多能性細胞の誘導及び自己再生並びにその使用 | |
| WO2018025975A1 (ja) | インビトロで多能性幹細胞を分化誘導する方法 | |
| HK40022436A (en) | Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells | |
| HK1232911A1 (en) | Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells | |
| HK1232911B (en) | Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells | |
| Engel | Harnessing the Power of Human Embryonic Stem Cells and Direct Reprogramming for Cardiac Regeneration | |
| Dawson | Cardiac Tissue Engineering | |
| Greta Maria | Cardiomyogenic differentiation of human multipotent stromal cells: a new approach fore regenerative medicine in cardiovascular disease. |